Kornimate/medical-research-clean huggingface dataset:
cancer and mild cognitive impairment dyadic intervention

Conditions: Cancer; Cognitive Impairment

Summary: the purpose of this study is to see whether programs that include both a patient and their spouse or a patient and family caregiver (known as a dyad) are helpful for families in which one member of the dyad has cancer and mild memory difficulties and/or concerns. participant and their spouse or participant and their family caregiver will have six, 60-minute video-conference sessions which will be scheduled at their convenience. the investigator will loan participants a tablet computer (ipad) to use for videoconferencing and train the participant in its use. participant and their spouse or participant and their family caregiver will complete three assessments - one before starting the sessions, one after the sixth session, and one after 1 month. each assessment will include surveys, which the participant will complete separately from their spouse or family caregiver. for most people, it will take upwards of 2 - 4 months to complete this study


Eligibility criteria:
inclusion criteria: patient inclusion criteria include: 1. patients with stage i-iv breast, colon, rectal, or lung cancer (diagnosed within two years); age 65 or older. 2. participants must be living at home (either in her/his own home). 3. participants must be fluent in english and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions. 4. exhibit mild cognitive impairment/concerns 5. have an informal family caregiver. inclusion criteria: (partner or family member) inclusion criteria include: 1. caregivers are 18 older. 2. be fluent in english and able to learn basic skills for using a tablet computer to conduct videoconference treatment sessions. 3. either co-reside with the patient or spend at least 3-4 hours day caregiving. 4. not exhibit cognitive impairment. exclusion criteria: 1. participant has visual or hearing impairments that preclude participation. 2. participant has dementia and do not have the capacity to participate. 3. have a serious untreated psychiatric illness as documented in medical chart review. 4. the patient and the caregiver score less than a 3 on the national comprehensive cancer network (nccn) distress thermometer (dt) on a scale 0 to 10 to screen for distress. at least one dyad member must experience distress.

Keywords: aging behavioral intervention mental health communication
intraoperative identification and stimulation of the glossopharyngeal nerve

Conditions: Head and Neck Cancer; Obstructive Sleep Apnea

Summary: published data suggest that the glossopharyngeal nerve innervates pharyngeal musculature important for maintenance of upper airway patency. the investigators propose a study examining the anatomic variation of the glossopharyngeal nerve and the effect of electrical stimulation on muscle recruitment and upper airway patency.

this is a single-arm physiology study. consenting patients undergoing parapharyngeal space (pps) surgery for tumor extirpation will undergo dissection of the glossopharyngeal nerve branches to the stylopharyngeus and pharyngeal constrictor muscles. fine-wire electrodes will be placed on these nerve branches. for each patient, if the target nerve branches can be identified and electrodes successfully placed, they will additionally undergo drug-induced sleep endoscopy (dise) immediately following pps surgery. per routine care, an incision is made across the neck to provide surgeons access to parapharyngeal space for tumor extirpation. during this dissection, the branch(es) of the glossopharyngeal nerve innervating the stylopharyngeus (sp) and pharyngeal constrictor (pc) muscles are exposed. for this study, measurements and photos/videos of the nerve will be taken. a fine-wire electrode will be placed on either or both successfully identified nerves and stimulated to assess muscle activation and changes in upper airway patency.

Eligibility criteria:
inclusion criteria: * consenting adults with bmi ≥ 25 and ≤ 40 kg/m2 * planned resection of parapharyngeal space (pps) mass without clinical evidence of cranial nerve function deficits based on physical examination * history of moderate-to-severe obstructive sleep apnea (osa) as confirmed by previous polysomnogram or high risk for osa based on stop-bang criteria (stop-bang score ≥ 3) exclusion criteria: * unable to consent for research due to a pre-existing neurologic condition or language barriers as determined by pi * history of other primary sleep-related breathing disorder (e.g., central, or complex sleep apnea). * previous pharyngeal surgery excluding tonsillectomy (e.g. cleft palate repair, uvulopalatopharyngoplasty) * prior history of head and/or neck chemoradiation therapy * existing indwelling neurostimulation device (e.g. pacemaker; spinal, vagal, or hypoglossal nerve stimulator)
targeted and staged cyber knife combined with interventional therapy in the treatment of mhcc

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma is a highly malignant tumor that is progressing rapidly. hepatic arterial embolization chemotherapy (tace) is a common method for the treatment of unresectable of hepatocellular carcinoma.but for patients with \> 10cm hepatocellular carcinoma, the intervention effect was not satisfied.the cyberknife is a kind of stereotactic radiotherapy which can track the movement of tumor and monitor the position deviation of tumor in real time.this stuy is aimed to observe the efficiency and safety of the combination of tace and cyberknife in the treatment of massive hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed hepatocellular carcinoma * no lymph node metastasis or distant metastasis * tumor diameter at least 10 cm * hepatic lesions are not suitable for surgical resection or the patient refuse to surgical treatment * eastern clinical oncology group (ecog)score is 0， 1or2 * no history of abdominal radiotherapy * inoperable and untransplantable,child-pugh score a or b * normal liver volume exceeds 700 cm3 exclusion criteria: * previous history of abdominal radiotherapy; * the maximum diameter of tumor is less than 10cm; * the liver child is graded c; * contraindication for radiotherapy; * active gastrointestinal bleeding occurred within 2 weeks before enrollment * pregnancy * undergoing chemotherapy throughout the past six months * diffuse hepatocellular carcinoma * main portal vein tumor embolization * undergoing other simultaneous treatment

Keywords: interventional therapy tace cyberknife
the effect of 4-7-8 breathıng exercıs after laparoscopıc surgery

Conditions: Pain

Summary: the study was a single-centre, parallel randomised controlled experimental study conducted with block randomisation method.

in determining the sample of the research, power analysis was performed and it was planned to have a total of 62 participants, with 31 participants in each group.women undergoing gynaecological operations will be recruited in the order of hospitalisation according to the block randomisation method. the letters a and b in the blocks will be determined as experimental or control according to the coin flip method. one of the researchers will evaluate the participants according to the inclusion criteria and randomly assign them according to the block order after obtaining their informed consent. one of the researchers in this study will carry out the application. the other researchers will be blinded. the data obtained will be analysed by an independent statistician. participant blinding will not be performed since the participants were informed about the study in informed consent. descriptive information form, mcgill pain scale short form (biçici, 2010) and vital signs assessment form to evaluate vital signs and mobilisation will be used for data collection.women who applied to the hospital due to benign gynaecological disorders and underwent laparoscopic surgery will first be evaluated whether they are eligible for the study according to the inclusion criteria evaluation form. afterwards, women who are eligible to participate in the study will be randomly assigned by an independent researcher to determine whether they are in the experimental or control group.

Eligibility criteria:
inclusion criteria: being literate, having benign gynaecological disease, not having any other disease affecting pain/living findings (neuropathy, migraine, cardiovascular diseases, oncological disease, ...), not using painkillers regularly, not having substance addiction, not having communication barrier. exclusion criteria: it was determined that women did not perform 4-7-8 breathing exercises regularly, women wanted to leave the study, complications related to surgery occurred at any stage of the study, women did not complete the data collection tools.

Keywords: 4-7-8 breathing exercises gynaecological surgery pain complication vital signs
envision: a study to evaluate the efficacy and safety of givosiran (aln-as1) in patients with acute hepatic porphyrias (ahp)

Conditions: Acute Hepatic Porphyria; Acute Intermittent Porphyria; Porphyria, Acute Intermittent; Acute Porphyria; Hereditary Coproporphyria (HCP); Variegate Porphyria (VP); ALA Dehydratase Deficient Porphyria (ADP)

Summary: the purpose of this study is to evaluate the effect of subcutaneous givosiran (aln-as1), compared to placebo, on the rate of porphyria attacks in patients with acute hepatic porphyrias (ahp).


Eligibility criteria:
inclusion criteria: * ≥ 12 years of age * diagnosed with acute hepatic porphyria (acute intermittent porphyria, hereditary corproporhyria, variegate porphyria, aminolevulinic acid (ala) dehydratase deficient porphyria) * elevated urinary or plasma porphobilinogen (pbg) or ala values within the past year, * have active disease, with at least 2 documented porphyria attacks within the last 6 months * willing to discontinue or not initiate the use of prophylactic hemin throughout the study. * women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception exclusion criteria: * clinically significant abnormal laboratory results * anticipated liver transplantation * history of multiple drug allergies or intolerance to subcutaneous injections * active hiv, hepatitis c virus, or hepatitis b virus infection(s) * history of recurrent pancreatitis

Keywords: acute intermittent porphyria (aip) acute hepatic porphyria (ahp) hereditary coproporphyria (hcp) variegate porphyria (vp) ala dehydratase deficient porphyria (adp) (alad) rnai therapeutic porphyria
employing esbi in hiv testing for at-risk youth

Conditions: HIV; Substance Use

Summary: the purpose of this study is to assess the feasibility, acceptability and test the initial efficacy of esbi, (electronic screening and brief intervention for alcohol use) coupled with sttr (seek, test, treat, and retain) in comparison to sttr only among ymsm (young men who have sex with men) and ytw (young transgender women) on frequency of substance use and engagement within the hiv (human immunodeficiency virus) and prep (pre-exposure prophylaxis) care continuum.

the purpose of this study is to assess the feasibility, acceptability and test the initial efficacy of esbi, (electronic screening and brief intervention for alcohol use) coupled with sttr (seek, test, treat, and retain) in comparison to sttr only among ymsm (young men who have sex with men) and ytw (young transgender women) on frequency of substance use and engagement within the hiv and prep (pre-exposure prophylaxis) care continuum. we will do this with the following aims: aim 1: assess the feasibility, acceptability and initial efficacy of electronic screening \& brief intervention + seek, test, treat and retain (esbi+ sttr) compared to sttr-only to reduce alcohol and other substance use among 450 ymsm and ytw in chicago, ages 16-25, at 1, 3, 6, and 12 months post-intervention. aim 2: to explore the initial efficacy of esbi+sttr in comparison to sttr-only on secondary exploratory outcomes within the hiv and prep care continuum among ymsm and ytw. aim 3: determine the degree to which sub-groups of youth are differentially impacted by esbi+sttr based on socio-demographic characteristics and co-morbid mental health problems to inform future targeting and/or tailoring of the intervention.

Eligibility criteria:
inclusion criteria: * aged 16 to 25 years * seeking testing for hiv infection * hiv-negative or hiv status unknown (per self-report) * male who has had sex with men or transgender woman who has had sex with men (i.e., born male, identify as female/transgender, and at any point in the gender transition process) * english-speaking. exclusion criteria: * volunteer seems distraught or emotionally unstable (i.e. suicidal, manic, exhibiting violent behavior) * volunteer seems intoxicated or under the influence of psychoactive agents

Keywords: hiv substance use
gemini symbicort pmdi

Conditions: Mild or Moderate Asthma

Summary: the purpose of this study is to determine whether treatment with symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.


Eligibility criteria:
inclusion criteria: * diagnosis of asthma * baseline lung function tests as determined by protocol. * required and received treatment with inhaled corticosteroids and/or lung treatments specified in the protocol within timeframe and doses specified in protocol. exclusion criteria: * severe asthma * has required treatment with any non-inhaled corticosteroid within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers * had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

Keywords: asthma inhaled corticosteroids symbicort budesonide/formoterol budesonide
rituximab in combination with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia

Conditions: Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Cancer

Summary: evaluation of safety profile and tolerability of mabthera (rituximab) in combination with chemotherapy (fludarabine and cyclophosphamide) in the treatment of chronic lymphocytic leukemia (cll).


Eligibility criteria:
inclusion criteria: * patients older than 18 years with diagnosed chronic lymphocytic leukemia (cll) * cll stages: binet stage c (rai iii or iv), binet stage b (rai i and ii) requiring treatment exclusion criteria: - patients who are not eligible for rituximab treatment according to summary of product characteristics (smpc)
dexmedetomidine pharmacokinetics-pharmacodynamics in mechanically ventilated children with single-organ respiratory failure

Conditions: Respiratory Failure

Summary: currently, dexmedetomidine is approved by the united states food and drug administration (fda) for short-term analgosedation (\<24h) in mechanically-ventilated critical care adult patients and sedation of non-intubated adult patients prior to and/or during surgical and other procedures. trials are underway to investigate its pharmacokinetics, clinical efficacy and safety in long-term use. clinical experience with dexmedetomidine in the paediatric population is limited. moreover, during childhood many developmental changes take place with consequences on drug exposure and drug response. finally, critical illness itself can affect drug pharmacokinetics and -dynamics. therefore, we cannot simply extrapolate adult data for use in children but we are in need of data on pharmacokinetics and pharmacodynamics in every paediatric subpopulation.


Eligibility criteria:
inclusion criteria: * patients (m/f) admitted to the paediatric intensive care unit * expected to require at least 24h of mechanical ventilation * patient age : 1 month-15 years * patients with single-organ respiratory failure exclusion criteria: * patients with neurologic conditions that prohibit an evaluation of adequate analgosedation * no arterial catheter in place at inclusion * patients who have received another investigational drug within 30 days * patients on continuous infusion with neuromuscular blockers * patients with a life expectancy \<72h * patients with a known allergy to lorazepam, midazolam and/or morphine * heart block * pre-existing bradycardia * hemodynamically unstable patients (wernovsky index \> 16 points) after full fluid replacement with crystalloid * patients with significant renal insufficiency (creatinine plasma level 1 month-5 year : \> 1 mg/dl ; 5-10 years : \>1.2 mg/dl; \> 10 years : \> 1.5 mg/dl) * patients with significant hepatic insufficiency (aspartate aminase \>950 ui/l and prothrombin time \ 1.4) * previous treatment with α2-adrenoreceptor agonist clonidine within 14 days

Keywords: patients with single-organ failure in need of mechanical ventilation
ret inhibitor for neoadjuvant therapy in locally advanced ret-altered thyroid cancer

Conditions: Thyroid Cancer

Summary: this study is a multicenter observational study. patients receive neoadjuvant therapy with ret inhibitors in the real world, and those who can undergo surgery after neoadjuvant therapy receive surgical treatment. the aim of the study is to determine the efficacy and safety of ret inhibitors for neoadjuvant therapy in locally advanced ret-altered thyroid cancer.


Eligibility criteria:
inclusion criteria: * patients voluntarily join this study and sign an informed consent form; * age: ≥ 14 years old, male or female not limited; * locally advanced thyroid cancer diagnosed by histopathology, including papillary thyroid carcinoma, medullary thyroid carcinoma, follicular thyroid carcinoma, poorly differentiated/poorly differentiated thyroid carcinoma, etc; * ret alterations, including fusion and mutations; * the definition of locally advanced thyroid cancer meets at least one of the following criteria: 1. local advanced thyroid cancer with estimated surgical difficulty and inability to r0/1 resection; 2. t4 thyroid cancer defined by ajcc: any size of tumor primary lesion or regional lymph node infiltration beyond the thyroid capsule to subcutaneous soft tissue, larynx, trachea, esophagus, or recurrent laryngeal nerve, tumor invasion of pre vertebral fascia or wrapping around carotid or mediastinal blood vessels; 3. according to the imaging score, the resectable probability is less than 80% based on ct. * at least one measurable lesion; * for patients with distant metastasis, researchers need to determine whether patients would benefit from surgery; * patients voluntarily undergo tumor tissue biopsy/surgery during enrollment and withdrawal; * normal function of major organs. exclusion criteria: * previously used ret inhibitors; * there are multiple factors that affect the absorption of oral medication, such as inability to swallow, nausea and vomiting, chronic diarrhea, and intestinal obstruction; * the patient refuses to undergo tumor tissue biopsy or surgery; * patients who are unsuitable for ret inhibitors or surgery.
the effect of isokinetic strengthening training

Conditions: Resistance Training; Stroke; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

Summary: our participants will include 40 patients within one month of stroke, 43 patients who received total hip replacement or total knee replacement two to four weeks before. the participants will be randomly assigned to isokinetic, isotonic or isometric training groups. outcome measures including isometric peak torque of hip/knee at 90 degree of flexion, peak torque of hip/knee at angular velocity of 60 degree/s and 120 degree/s, short form 36 (sf-36), the timed up and go test, the oxford hip/knee score, the plasma concentration of hscrp, and the level of substance p in saliva will be collected at the beginning and 4 weeks after the training program. statistical significant differences will be determined between the improvement of outcome measures of the isokinetic and the isotonic training groups.

our participants will include 40 patients within one month of stroke, 43 patients who received total hip replacement or total knee replacement two to four weeks before. the participants will be randomly assigned to isokinetic, isotonic or isometric training groups. outcome measures including isometric peak torque of hip/knee at 90 degree of flexion, peak torque of hip/knee at angular velocity of 60 degree/s and 120 degree/s, short form 36 (sf-36), the timed up and go test, the oxford hip/knee score, the plasma concentration of hscrp, and the level of substance p in saliva will be collected at the beginning and 4 weeks after the training program. statistical significant differences will be determined between the

Eligibility criteria:
inclusion criteria: * within one month of acute stroke * receive total hip/knee replacement within two to four weeks before exclusion criteria: * cannot perform from sitting to standing * body mass index \> 30 * lower limbs fracture history * diabetic polyneuropathy * cardiopulmonary diseases that impede exercise prescription * impaired cognitive function * infectious disease during the study period that may cause cytokine changes
special investigation in patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: this investigation will be conducted to obtain the following information regarding the use of humira 40 mg syringe 0.8 ml for subcutaneous injection in patients with ulcerative colitis. 1. unknown adverse reactions (in particular, clinically significant) 2. incidence and conditions of occurrence of adverse reactions in clinical practice 3. factors likely to affect the safety and effectiveness


Eligibility criteria:
inclusion criteria: * patients receiving humira for the first time for the treatment of ulcerative colitis exclusion criteria: contraindications according to the package insert include patients who have any of the following: * serious infections * tuberculosis * a history of hypersensitivity to any ingredient of humira * demyelinating disease or a history of demyelinating disease * congestive cardiac failure

Keywords: ulcerative colitis
a shared decision making training for inpatients with schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: patients suffering from schizophrenia who attend the communication skills program engage more deeply in therapeutic reasoning and treatment decisions. this results in stronger preferences to participate, greater perceived involvement and better long term adherence compared to patients who do not attend the training.


Eligibility criteria:
inclusion criteria: * male and female inpatients with a diagnosis of schizophrenia/schizoaffective disorder according to icd 10 * between 18 and 60 years of age are eligible for the study * informed consent * inpatients exclusion criteria: * poor german language skills